Balance Sheet: Liabilities and Stockholders’ Equity
The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Regeneron Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity
US$ in thousands
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The financial data demonstrates multiple evolving trends in liabilities and equity over the five-year period ending in 2024.
- Current Liabilities
- Accounts payable showed a steady increase, rising from approximately 475.5 million in 2020 to nearly 789.5 million by 2024, indicating a growing obligation to suppliers or creditors. Accrued payroll and related costs fluctuated, initially decreasing from 465.8 million in 2020 to 440.7 million in 2021, but then rising substantially to 640.9 million by 2024, hinting at increased workforce or compensation-related commitments. Accrued clinical expenses remained relatively stable around the 280 to 315 million range, showing consistency in clinical-related payables. Accrued sales-related costs increased sharply, nearly doubling from 423.9 million in 2020 to 786.2 million in 2024, reflecting growing sales activities and associated costs.
- Income tax-related costs appear only in 2023 and 2024, rising significantly from 11.7 million to 213.2 million, suggesting either changes in tax obligations or reporting. Other accrued expenses and liabilities showed volatility, peaking at nearly 998 million in 2021 before decreasing to 571.1 million in 2024. Overall, accrued expenses and other current liabilities grew substantially, from 1.64 billion in 2020 to 2.53 billion in 2024, highlighting an increase in short-term obligations.
- Deferred revenue decreased from 577.7 million in 2020 to 442 million in 2021, then oscillated slightly, rising sharply to 627.7 million by 2024, indicating variations in prepaid revenue or customer advances. Current liabilities followed a general upward path from 2.7 billion in 2020 to 3.94 billion in 2024, reflecting an expansion in short-term liabilities overall.
- Noncurrent Liabilities
- Long-term debt remained relatively static, holding steady around 1.98 billion across the entire period, indicating minimal changes in borrowing. Finance lease liabilities showed fluctuations; current portions were only disclosed in 2021 at 719.7 million and absent in other years, while noncurrent portions remained steady at about 720 million from 2020 to 2024. Deferred revenue in noncurrent liabilities increased from 57.8 million in 2020 to 185.7 million in 2024, suggesting growth in long-term customer prepayments or contractual obligations.
- Other noncurrent liabilities exhibited a marked increase, starting at 687.1 million in 2020, dipping slightly, then more than doubling to 1.57 billion by 2024. Noncurrent liabilities as a whole grew from 3.44 billion in 2020 to 4.46 billion in 2024, revealing rising long-term obligations.
- Total Liabilities
- Total liabilities expanded steadily from 6.14 billion in 2020 to 8.41 billion in 2024. This growth was driven by increases in both current and noncurrent liabilities, reflecting an overall enlargement of the company’s debt and obligations profile.
- Stockholders’ Equity
- Common stock par value remained constant at 100 thousand, while additional paid-in capital showed a strong upward trajectory, increasing from 6.72 billion in 2020 to 12.86 billion in 2024, which indicates new capital inflows or retained value from equity issuances. Retained earnings consistently rose, nearly tripling from 10.89 billion to 31.67 billion over the five years, signaling sustained profitability and reinvestment of earnings.
- Accumulated other comprehensive income (loss) fluctuated, experiencing negative values from 2021 through 2024, but the magnitude of losses decreased in recent years, implying some recovery in unrealized gains or foreign currency translation adjustments. Treasury stock at cost increased substantially in its negative balance, from -6.61 billion in 2020 to -15.17 billion in 2024, indicating significant stock repurchase activities reducing outstanding shares.
- Overall stockholders’ equity increased markedly from 11.03 billion in 2020 to 29.35 billion in 2024, supported by increases in paid-in capital and retained earnings despite the negative impact of treasury stock and accumulated losses.
- Total Liabilities and Equity
- The combined total of liabilities and stockholders’ equity consistently rose from 17.16 billion to 37.76 billion, reflecting growth in the scale of the organization’s financial structure.